ArticleJournal of inflammation research2025
Dual Effects of Sodium Houttuyfonate Against Acute Rhinosinusitis: Antibacterial Action and Epithelial Barrier Repair Through the p38 MAPK/ERK Pathway.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibacterial and Immunomodulatory Activities of a Natural Polysaccharide AgainstFood science & nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Network pharmacology was applied to identify SH-associated targets and pathways. An ARS rat model was induced by inserting Staphylococcus aureus-soaked Merocel sponges into the nasal cavity. Rats received low, medium, or high doses of SH, with control and positive drug groups. Symptom scoring, CT, histopathology, hematology, ELISA, qRT-PCR, and immunohistochemistry were conducted. In vitro, human nasal epithelial cells (HNEpCs) were stimulated with lipopolysaccharide (LPS) and treated with SH, with or without MAPK modulators SB203580 (inhibitor) or Anisomycin (activator). Cell viability, cytokine expression, and ERK/p38 MAPK phosphorylation were assessed. Results: SH improved nasal symptoms, reduced epithelial injury, and normalized nasal pH in ARS rats. It downregulated IL-1β, IL-6, TNF-α, and ICAM-1 while upregulating IL-4. Transmission electron microscopy showed restoration of ciliary and mitochondrial integrity. In HNEpCs, 60 μM SH was optimal by CCK-8 assay. In LPS-stimulated cells, SH suppressed IL-1β/IL-6 mRNA and inhibited ERK and p38 MAPK phosphorylation; these effects were reversed by Anisomycin, confirming pathway involvement. Conclusion: SH alleviates sinonasal inflammation in ARS by inhibiting bacterial activity and restoring epithelial integrity through p38 MAPK/ERK suppression. These findings support SH as a potential therapy for upper airway inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.